MA46539A - Structures et mécanisme pour la conception de glucocorticoïdes hautement puissants - Google Patents

Structures et mécanisme pour la conception de glucocorticoïdes hautement puissants

Info

Publication number
MA46539A
MA46539A MA046539A MA46539A MA46539A MA 46539 A MA46539 A MA 46539A MA 046539 A MA046539 A MA 046539A MA 46539 A MA46539 A MA 46539A MA 46539 A MA46539 A MA 46539A
Authority
MA
Morocco
Prior art keywords
glucocorticoids
structures
design
highly powerful
powerful
Prior art date
Application number
MA046539A
Other languages
English (en)
Inventor
Yuanzheng He
Huaqiang Eric Xu
Original Assignee
Van Andel Res Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Van Andel Res Institute filed Critical Van Andel Res Institute
Publication of MA46539A publication Critical patent/MA46539A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0036Nitrogen-containing hetero ring
    • C07J71/0042Nitrogen only
    • C07J71/0047Nitrogen only at position 2(3)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA046539A 2016-10-14 2017-10-13 Structures et mécanisme pour la conception de glucocorticoïdes hautement puissants MA46539A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662408314P 2016-10-14 2016-10-14

Publications (1)

Publication Number Publication Date
MA46539A true MA46539A (fr) 2019-08-21

Family

ID=61906432

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046539A MA46539A (fr) 2016-10-14 2017-10-13 Structures et mécanisme pour la conception de glucocorticoïdes hautement puissants

Country Status (12)

Country Link
US (1) US10954265B2 (fr)
EP (1) EP3525870B1 (fr)
JP (2) JP7146750B2 (fr)
KR (1) KR102497070B1 (fr)
CN (1) CN110382033B (fr)
ES (1) ES2945983T3 (fr)
MA (1) MA46539A (fr)
PH (1) PH12019500801A1 (fr)
RU (1) RU2019111101A (fr)
SG (1) SG11201903209TA (fr)
WO (1) WO2018071736A1 (fr)
ZA (1) ZA201902595B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025119398A1 (fr) * 2023-12-08 2025-06-12 浙江柏拉阿图医药科技有限公司 Polymorphe de glucocorticoïde à efficacité élevée, son procédé de préparation et son utilisation
CN120365344A (zh) * 2024-01-24 2025-07-25 浙江柏拉阿图医药科技有限公司 一种高效力糖皮质激素化合物及其制备和用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK66202C (da) 1945-03-03 1948-01-12 Danske Securitas As Kodekontakt til elektriske Alarmanlæg.
DK71662C (da) 1946-09-05 1950-11-06 Ingenioer Frank Broadbent Tørrecentrifuge.
US4049813A (en) 1976-07-15 1977-09-20 Sandoz, Inc. Substituted isoxazolo pyridinones
US5837698A (en) * 1996-05-02 1998-11-17 G. D. Searle & Co. Steroid nitrite and nitrate ester derivatives useful as anti-inflammatory drugs
EP1408042A4 (fr) 2001-06-14 2005-02-02 Banyu Pharma Co Ltd Nouveaux derives d'isoxazolopyridone et leur utilisation
GB0119911D0 (en) 2001-08-15 2001-10-10 Novartis Ag Organic Compounds
SG148186A1 (en) * 2003-11-13 2008-12-31 Combinatorx Inc Methods and reagents for the treatment of inflammatory disorders
CA2621117A1 (fr) * 2005-09-02 2007-03-08 Nicox S.A. Nitro-oxyderives de steroides
CN1813768A (zh) * 2005-11-18 2006-08-09 成都力思特制药股份有限公司 治疗呼吸系统疾病的药用组合物及其在制药中的应用
AU2008306593C1 (en) * 2007-10-04 2012-10-04 Astrazeneca Ab Steroidal [3, 2-C] pyrazole compounds, with glucocorticoid activity
CA2707618A1 (fr) * 2007-12-20 2009-07-02 Astrazeneca Ab Derives de steroides agissant comme des agonistes des recepteurs de glucocorticosteroides
WO2010083218A1 (fr) 2009-01-13 2010-07-22 Van Andel Research Institute Méthodes d'utilisation de pyridinones isoxazolo-substituées en tant que glucocorticoïdes
UY32520A (es) 2009-04-03 2010-10-29 Astrazeneca Ab Compuestos que tienen actividad agonista del receptor de glucocorticoesteroides
UY32523A (es) * 2009-04-03 2010-10-29 Astrazeneca Ab Compuestos que tienen actividad agonista del receptor de glucocorticosteroides
UY32525A (es) * 2009-04-03 2010-10-29 Astrazeneca Ab Compuestos que tienen actividad agonista del receptor de glucocorticosteroides
CA2764830A1 (fr) * 2009-06-16 2010-12-23 Schering Corporation Nouveaux [3,2-c] heteroaryl steroides en tant qu'agonistes des recepteurs glucocorticoides, compositions et utilisations de ceux-ci
EP3049089B1 (fr) 2013-09-25 2019-08-21 Van Andel Research Institute Glucocorticoïdes très puissants
TWI695831B (zh) * 2014-09-13 2020-06-11 香港商南北兄弟藥業投資有限公司 Crth2拮抗劑化合物及其用途

Also Published As

Publication number Publication date
KR20190068577A (ko) 2019-06-18
CN110382033B (zh) 2022-04-15
PH12019500801A1 (en) 2019-11-11
EP3525870B1 (fr) 2023-05-10
CN110382033A (zh) 2019-10-25
SG11201903209TA (en) 2019-05-30
WO2018071736A1 (fr) 2018-04-19
KR102497070B1 (ko) 2023-02-06
JP2019532071A (ja) 2019-11-07
JP7146750B2 (ja) 2022-10-04
WO2018071736A9 (fr) 2019-05-23
ES2945983T3 (es) 2023-07-11
ZA201902595B (en) 2021-04-28
EP3525870A1 (fr) 2019-08-21
JP2022132464A (ja) 2022-09-08
EP3525870A4 (fr) 2020-04-29
US10954265B2 (en) 2021-03-23
RU2019111101A3 (fr) 2020-11-27
US20190263853A1 (en) 2019-08-29
RU2019111101A (ru) 2020-11-16

Similar Documents

Publication Publication Date Title
EP3408858A4 (fr) Structures de graphène pour supercondensateurs
EP3364904A4 (fr) Balayage variable pour dispositifs d'entrée
EP3718819A4 (fr) Mécanisme de retournement
EP3468536A4 (fr) Colloïdosomes à nano-architecture pour libération régulée et déclenchée
EP3630078A4 (fr) Agents pour chimio-embolisation
PT3368534T (pt) Ditosilato de valbenazina e polimorfos do mesmo
SG11202008388TA (en) Movement assistance device
IL264143B (en) Processes for preparing olaparib
HUE055263T2 (hu) 11-Szubsztituált 24-hidroxiszterolok NMDA-hoz kapcsolódó állapotok kezelésére
SG10201701420WA (en) Inspection of Structures
EP3721849A4 (fr) Dispositif d'aide
EP3519028A4 (fr) Étrier pour harnais
HUE054542T2 (hu) Glükokortikoid receptor inhibitor
EP3403775A4 (fr) Dispositif d'assistance
EP3434358A4 (fr) Mélangeur de liquéfaction
EP3722105C0 (fr) Dispositif de roulette s'adaptant à une marche
EP3603599A4 (fr) Dispositif d'assistance
DK3569211T3 (da) Assistanceindretning
EP3405864A4 (fr) Mystification cpuid pour rétrocompatibilité
EP3412054A4 (fr) Technique de reconfiguration basée sur une priorité pour des unités à distance
IL259391B (en) Hydroxamate triterpenoid derivatives
PT3411535T (pt) Dispositivo de chuveiro
FR3055892B1 (fr) Materiau silicate de structure olivine
DK3495571T3 (da) Bruseanordning
EP3525870A4 (fr) Structures et mécanisme pour la conception de glucocorticoïdes hautement puissants